Peptide Synthesis Market

The global peptide synthesis market in terms of revenue was estimated to be worth $601 million in 2023 and is poised to reach $859 million by 2028, growing at a CAGR of 7.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Various elements such as increasing R&D activities, increasing government funding for drug discovery research, and growing pharmaceutical & biological industries are the major growth factors for this market. Many peptide-based research projects are also being fostered by increasing collaborative partnerships among various companies this factor is further driving market growth.

Attractive Opportunities in the Peptide Synthesis Market

To know about the assumptions considered for the study, Request for Free Sample Report

Peptide Synthesis Market Dynamics

DRIVER: Increasing use of peptides in pharmaceutical drugs

Peptides are highly active and highly specific drug substances. Due to the diversity of their biological functions, they are used in an extensive range of therapeutic areas. Peptides are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, high biological activity, high specificity, relative ease of synthesis, ready availability, and low toxicity. The increasing use of peptides in the pharmaceutical industry can be attributed to their therapeutic potential, high specificity and low toxicity, versatility and diversity, advancements in peptide synthesis technologies, their application as drug candidates, the emergence of personalized medicine, and the growing research and investment in peptide-based therapeutics. These factors collectively contribute to the rising prominence of peptides as a valuable class of molecules in the development of novel and targeted pharmaceutical therapies.

RESTRAINT: High cost of instruments

The synthesis of proteins involves the use of rapid, high-throughput systems. Peptide synthesizers and chromatography equipment with advanced features and functionalities are generally priced at a premium. Peptide synthesizers are either fully automated, manual, or semi-automated and offer users complete control over the synthesis process. The cost of peptide synthesizers ranges from USD 300,000 to 250,000 based on the automation and advanced features accommodated. Such high prices of instruments make it difficult for developing countries to venture into peptide synthesis. Technological advancements have resulted in the high cost of these instruments. Moreover, the maintenance of these instruments is a costly affair, which involves spares, chemicals, consumables, and timely servicing. Furthermore, the use of these instruments requires a highly trained workforce. These factors restrict the growth of the peptide synthesis industry to a certain extent in developing regions.

OPPORTUNITY: Development of personalized medicines

The development of personalized medicine creates substantial growth opportunities for the peptide synthesis industry. Peptides offer the required specificity, customization, and targeting capabilities to support personalized treatment approaches. As personalized medicine continues to evolve and gain prominence, the demand for peptide synthesis technologies, services, and products is expected to grow significantly.

CHALLENGE: Issues associated with the route of administration of peptide drug

The majority of therapeutic peptides are administered by the parenteral route because of insufficient absorption from the gastrointestinal tract. Peptide drugs are usually indicated for chronic conditions, and the use of injections on a daily basis during long-term treatment has significant drawbacks. In contrast to this inconvenient and potentially problematic method of drug administration, the oral route offers advantages such as self-administration with a high degree of patient acceptability and compliance. The main reasons for the low oral bioavailability of peptide drugs are pre-systemic enzymatic degradation and poor penetration of the intestinal mucosa. Also, these therapeutics tend to have a high molecular weight, low lipophilicity, and charged functional groups that hamper their absorption. These characteristics lead to the low bioavailability of most orally administered peptides and short half-lives. Addressing these challenges is critical for advancing peptide research. Hence, it can be considered a challenge for the market.

Peptide Synthesis Market – Ecosystem

The Reagents segment dominated peptide synthesis industry in 2022

Based on product & service, the peptide synthesis market is segmented into reagents, equipment, and services. In 2022, the reagents segment accounted for the largest share of the market. The large share of this segment can be attributed to the growth of peptide synthesis reagents is fueled by the expanding field of peptide-based therapeutics, increasing research activities, customized peptide libraries, technological advancements; and the availability of various peptide synthesis reagents in the market.

North America dominated the peptide synthesis industry in 2022.

To know about the assumptions considered for the study, download the pdf brochure

Geographically, the peptide synthesis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2022, North America accounted for the largest share of the market, followed by Europe and the Asia Pacific. The large share of the North American market is owing to various factors such presence of a large number of pharmaceutical companies and the growing demand for personalized medicines. Increased research funding for peptide & protein-based research is furthermore driving market growth in North America.

Key players in the peptide synthesis market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Kaneka Corporation (Japan), GenScript Biotech Corporation (China), and Bachem Holding AG (Switzerland).

Scope of the Peptide Synthesis Industry

This report categorizes the peptide synthesis market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

• Reagents
  • Resins
  • Amino acids
  • Coupling Reagents
  • Dyes and Fluorescent labeling reagents
  • Other Reagents
• Equipment
  • Peptide Synthesizers
  • Chromatography Equipment
  • Lyophiizers
• Services

By Technology

• Solid-Phase Peptide Synthesis
• Solution-Phase Peptide Synthesis
• Hybrid & Recombinant Technology

By End User

• Pharmaceutical & Biotechnology companies
• CDMOs & CROs
• Academic & Research Institutes

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
  • Brazil
  • Mexico
  • RoLATAM
• Middle East and Africa (MEA)

Recent Developments of Peptide Synthesis Industry

• In January 2023, Merck announced an agreement to acquire the peptide synthesis company Asymchem. This acquisition will give Merck access to Asymchem's expertise in peptide synthesis and its global manufacturing network.
• In December 2022, Thermo Fisher announced an agreement to acquire the peptide synthesis company Protagen. This acquisition will give Thermo Fisher access to Protagen's expertise in peptide synthesis and its global manufacturing network.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst